lobbying_activities: 1295817

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1295817	a5317b72-98f5-4838-8b04-3887f7fc33d2	Q3	HOLLAND & KNIGHT LLP	18466	ALLIANCE FOR REGENERATIVE MEDICINE	2012	third_quarter	HCR	Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in HR 5651 & S. 3187 Patient Centered Outcomes Research Institute (PCORI). Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 the FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products. Drafted and submitted comments on proposed "methodology report" regarding comparative effectiveness research from the Patient Centered Outcome Research Institute.	Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE	80000		0	0	2012-10-08T14:14:36.857000-04:00